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Abstract
Purpose This study aimed to report the use of intravitreal
bevacizumab as an adjunctive treatment in two cases of
advanced Eales’ disease with vitreous haemorrhage and
tractional retinal detachment, prior to vitreoretinal surgery.
Method In two patients presenting with vitreous haemor-
rhage, retinal neovascularisation and localised tractional
retinal detachment, 1.25 mg of intravitreal bevacizumab
was injected prior to vitrectomy, membrane peeling and
endolaser photocoagulation of retina.
Result Regression of the retinal neovascularisation with
resolution of dye leakage on fluoroscein angiography was
observed in both cases. Membrane peeling could be
performed with minimal bleeding during vitreoretinal
surgery in both cases.
Conclusion Bevacizumab may be a possible adjunctive
treatment to vitreoretinal surgery for the management of
Eales’ disease with tractional retinal detachment.
Keywords Bevacizumab.Eales’ disease.Tractional retinal
detachment
Introduction
Eales’ disease although occurring worldwide is encountered
commonly in the Indian subcontinent. It affects healthy
young adults aged 20–30 years with a male preponderance
[1]. The characteristic clinical features include occlusive
peripheral retinal vasculitis leading to capillary non-
perfusion and ischemia followed by neovascularisation of
the disc and retina and subsequently recurrent vitreous
haemorrage and tractional retinal detachment. Photocoagula-
tion is the mainstay of therapy in the proliferative stage of
Eales’ disease [2].
Recently, intravitreal bevacizumab has been explored as
a possible therapeutic modality in the management of early
stages of Eales’ disease [2–5]. We report two cases of
Eales’ disease with tractional retinal detachment where
bevacizumab was used intravitreally as an adjunctive
treatment prior to vitreoretinal surgery. To our knowledge,
this is probably the first report where adjunctive bevacizumab
used preoperatively in a relatively advanced stage of the
disease facilitated the removal of fibrovascular membranes
with minimal intra- and post-operative complications.
Case 1
A 28-year-old female presented with complaint of sudden,
painless, progressive diminution of vision in her right eye
since last 10 months. On examination of the right eye, the
best corrected visual acuity (BCVA) was counting finger at
2 m. Anterior segment was normal on slit lamp biomicro-
scopy. The intraocular pressure was also normal. Fundus
evaluation revealed retinal and disc neovascularisation with
the presence of a fibrovascular band temporal to the disc.
There was vitreous haemorrage and tractional retinal
detachment inferiorly in the retina. Vitreous haemorrhage
and inferior tractional retinal detachment were confirmed
further on ultrasound B scan. Leakage of dye from the
retinal neovascularisation superior to the disc and staining
of the fibrovascular band temporal to the disc was evident
on fluorescein angiogram (FA) (Fig. 1a, b). Peripheral
capillary non-perfusion areas were noted in the superior
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trauma 10 years back. Systemic examination, past medical
and drug history were unremarkable. Investigations to rule
out secondary vasculitis revealed normal haemogram,
erythrocyte sedimentation rate, coagulation profile and
blood sugar (fasting and post-prandial). Rheumatoid factor
(RF) and Venereal Disease Research Laboratory (VDRL)
test were negative. Antinuclear antibody (ANA) was not
detected. Test for HIV I and HIV II was negative. Sickle
cell preparation was normal. Mantoux test was negative.
The chest radiograph was normal. A diagnosis of Eales’
disease was made. An informed consent was obtained from
the patient for bevacizumab injection after the “off-label”
status of bevacizumab and its possible systemic and ocular
complications were discussed in detail. From a commer-
cially available 4 ml vial containing 100 mg bevacizumab
(Avastin, Genetech Inc, CA, USA), 0.05 ml (containing
1.25 mg) was withdrawn into in a tuberculin syringe using
aseptic techniques. After preparing the eye in a standard
fashion using 5% povidone/iodine, an eyelid speculum was
used to stabilise the eyelids, and bevacizumab (0.05 ml)
was injected 4 mm posterior to the limbus, through the pars
plana with a 30-gauge needle under subconjunctival
lignocaine. Following the injection, intraocular pressure
and retinal artery perfusion were confirmed, and patient
was instructed to administer topical ofloxacin eyedrops for
7 days.
Six weeks post-injection, vitreoretinal surgery was
performed with membrane peeling and endolaser photoco-
agulation. Membrane peeling was easily performed without
the need of diathermy during surgery. On the first post-
operative day, adequate fundal glow indicated proper
haemostasis without post-operative oozing. At 2 weeks
follow-up, BCVA in the right eye improved to 6/36
(Snellen chart). On fundus evaluation, there was absence
of retinal or disc neovascularisation. Fluorescein angiogram
(Fig. 1c, d) revealed absence of leakage from regressed
vessels and an appropriately lasered peripheral retina.
Staining of the inferotemporal vessel seen in the late phase
indicated healed vasculitis. At 6 months follow-up, BCVA
was maintained without recurrence of neovascularisation or
vitreous haemorrhage.
Case 2
A 19-year-old male presented with complaints of sudden,
painless, progressive diminution of vision in the left eye for
last 4 months. The BCVA in the left eye was counting
finger at 2 m. Anterior segment was normal on slit lamp
Fig. 1 Fundus photograph and
fluorescein angiogram (FA) of
the right eye of Case 1 at
presentation (a and b) and after
vitreoretinal surgery (c and d).
a Disc neovascularisation,
retinal neovascularisation
superior to the disc, presence of
fibrovascular band temporal to
the disc and inferior tractional
retinal detachment with inferior
vitreous haemmorhage. b (FA):
Leakage of dye from the retinal
neovascularisation superior to
the disc and staining of the
fibrovascular band temporal to
the disc. c Well-settled retina
with endolaser marks. d (FA):
Absence of dye leakage with
complete regression of
neovacularisation and adequately
lasered peripheral retina
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frond extending from the disc superiorly along with
superior tractional retinal detachment and inferior vitreous
haemorrage. Leakage of dye from the neovascular frond
was revealed in FA (Fig. 2a, b). The right eye was normal
with visual acuity of 6/6. Systemic examination, past
medical and drug history were unremarkable. Haematological
investigations and other tests conducted to rule out secondary
vasculitis including haemogram, erythrocyte sedimentation
rate, coagulation profile, blood sugar and sickle cell prepara-
tion were normal. RF, ANA, VDRL, HIV I, HIV II and
Mantoux test were negative. The chest radiograph was also
normal. A diagnosis ofEales’ disease was made. Aninformed
written consent was obtained and bevacizumab was injected
intravitreally(1.25mg/0.05ml)throughparsplanainasimilar
fashion as the previous case with a 30-gauge needle under all
aseptic precautions.
Four days post-injection, fundus evaluation and fluores-
cein angiogram revealed mild regression of new vessels and
persistence of the dye leakage. Twenty days later, repeat FA
showed staining of fibroglial tissue without any leakage of
dye from the regressed vessels (Fig. 2c, d). On 21st day
post-injection, a three-port pars plana vitrectomy was
performed along with membrane peeling followed by
endolaser photocoagulation and silicone oil tamponade.
There was minimal bleeding during membrane peeling.
Post-operatively, the patient was prescribed with ofloxacin
drops four times a day and prone positioning was advised.
On the first post-operative day, there was adequate fundal
glow and the retina appeared settled with silicone oil in situ
and endolaser marks could be visualised. Four weeks later,
BCVA improved to 6/60.
Discussion
It is well established that retinal ischaemia stimulates the
production of vascular endothelial growth factor (VEGF), a
key mediator of angiogenesis. Massive expression of VEGF
in the neovascular membranes in Eales’ disease has also
been reported previously [6, 7]. Bevacizumab, a humanised
monoclonal antibody against VEGF, is currently emerging
as an effective off-label treatment for a variety of ocular
disorders such as neovascular age-related macular degener-
ation, macular edema secondary to central retinal vein
occlusion and proliferative diabetic retinopathy [8]. However,
a literature search revealed only few anecdotal reports on the
use of intravitreal bevacizumab in Eales’ disease [2–5]. In all
Fig. 2 Fundus photograph and
fluorescein angiogram of the left
eye of Case 2 at presentation
(a and b) and 20 days after
bevacizumab injection (c and d).
a Presence of fibrovascular
frond extending from the disc
superiorly and superior traction-
al retinal detachment. b (FA):
Leakage of dye from neovascu-
larisation superior to the disc
and staining of fibrovascular
band. c Marked regression of the
new vessels. d (FA): Staining
of the glial tissue without any
dye leakage
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disease without retinal detachment. In contrast, our cases had
fairly advanced Eales’ disease with tractional retinal detach-
ment, and bevacizumab was effective in promoting regression
of neovascularisation, thus facilitating membrane dissection
by reducing intra-operative bleeding. Additionally, due to
better visibility during surgery, the chances of causing
iatrogenic retinal breaks were also reduced. Although photo-
coagulation is the preferred modality of treatment in the
proliferative stage of Eales’ disease, it could not be performed
in both our cases due to the presence of dispersed vitreous
haemorrhage and tractional retinal detachment. Nevertheless,
there was no recurrence of neovascularisation at 6 months
follow-up in our first patient, and at the time of writing this
report, the second patient had been followed up for 2 months
without recurrence of neovascularisation.
In both our cases, sequential treatment with bevacizumab
followed by vitrectomy was beneficial and associated with
fair visual outcome, despite the presence of tractional
retinal detachment. However, the appropriate time interval
between bevacizumab injection and vitreoretinal surgery in
the presence of tractional retinal detachment is not
established. The minimum concentration (500 ng/ml) of
intravitreal bevacizumab (1.25 mg) that completely inhibits
VEGF-A-induced endothelial cell proliferation is reportedly
maintained for 6–7 weeks, after which repeat administration
of bevacizumab may be required [9]. We performed
vitreoretinal surgery within 3–6 weeks after injection of
bevacizumab as the anti-angiogenic effect of drug was
expected to be maintained during this period while allowing
reasonably sufficient time for regression of neovascularisa-
tion. Additionally, in our first case, non-recurrence of
neovascularisation at 6 months follow-up suggests that
intermediate-term control is achievable with intravitreal
bevacizumab and vitreoretinal surgery, even with a back-
ground of ongoing ischemic disease. Although recent
studies have strengthened the favourable short-term safety
profile of intravitreal bevacizumab, long-term safety of
intravitreal bevacizumab is still unknown [10]. Therefore,
prudent clinical judgement and caution should be exercised
with the off-label use of intravitreal bevacizumab, as there
have been few reports of progression of tractional retinal
detachment in patients with severe proliferative diabetic
retinopathy [11].
To summarise, the use of intravitreal bevacizumab
provided a relatively clean surgical field and facilitated
membrane dissection with reduced chance of iatrogenic
retinal break. Therefore, bevacizumab may have potential
as an adjunctive treatment to vitreoretinal surgery for the
management of Eales’ disease with tractional retinal
detachment. However, well-designed randomised controlled
trials are essential before such a use can be unequivocally
established.
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